ProMIS Neurosciences, Inc. PMN
3.63 USD -0.13 (-3.46%)
Nov 12, 2026, 12:23 PM EST
3.40 Day range 3.76
2.78 52-week range 27.40
- YTD
- -46.85%
- 1 year
- -64.59%
News
globenewswire.com ProMIS Neurosciences to Participate in Upcoming Conferences in November CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic…
benzinga.com Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15 Roth Capital analyst Boobalan Pachaiyappan maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $29 to $15.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development…
benzinga.com Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100 Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.- benzinga.com ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs.…
benzinga.com ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of…
benzinga.com Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69 Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $35 to $69.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out…
benzinga.com Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
benzinga.com Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33 Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $20 to $33.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
benzinga.com Market-Moving News for July 28th AMKR: -9% | Amkor Technology shares are trading lower after the company reported Q2 financial results and issued Q3 sales guidance below estimates. PMN: 32% | ProMIS Neurosciences shares are trading…- benzinga.com ProMIS Neurosciences Announces Six-Month Interim Safety And Biomarker Results From Its PRECISE-AD Phase 1B Trial Of PMN310 In Patients With Mild Cognitive Impairment Due To Alzheimer’s; Early Biomarker Movement Consistent With Target Engagement In the blinded interim analysis evaluating 136 AD patients, PMN310 was observed to have a favorable safety profile across all genotypes, with no cases of amyloid-related imaging abnormalities-edema…
benzinga.com Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
- benzinga.com Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20 Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.
- benzinga.com ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected Soon PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteersRepresents one of the first quantitative measures of…
- benzinga.com Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $19.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
- benzinga.com Cantor Fitzgerald Initiates Coverage On ProMIS Neurosciences with Overweight Rating Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Overweight rating.
benzinga.com HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of…- benzinga.com CORRECTION: ProMIS Neurosciences Q4 EPS $(3.11) Misses $(0.21) Estimate ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(3.11) per share which missed the analyst consensus estimate of $(0.21) by 1380.95 percent. This is a 522 percent decrease over losses…
- benzinga.com ProMIS Neurosciences To Highlight Data On ALS & Parkinsons Disease Programs At AD/PD 2026 International Conference ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35 Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com ProMIS Neurosciences Announces $175M Private Placement Financing 6,090,075 Common Shares were sold at a price of $10.77 per Common Share, 100,000 Pre-Funded Warrants were sold at a price of $10.77 less an exercise price $0.0001 per Warrant Share and 725,221 Common…- benzinga.com ProMIS Neurosciences Completes Enrollment Of 144 Patients In PRECISE-AD Phase 1b Clinical Trial, Evaluating PMN310, Therapeutic Antibody Candidate For Treatment Of AD Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's diseaseClear and near-term value inflection points, with blinded 6-month…
- benzinga.com ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in…
- benzinga.com HC Wainwright & Co. Maintains Buy on ProMIS Neurosciences, Raises Price Target to $18 HC Wainwright & Co. analyst Raghuram Selvaraju maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $4 to $18.
- benzinga.com ProMIS Neurosciences Highlights New Peer-Reviewed Publication Showing Plasma pTau as Predictive Early Endpoint in Alzheimer's Trials Supporting PRECISE-AD Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trialProMIS on track to leverage new plasma…
- benzinga.com ProMIS Neurosciences Highlights Plasma pTau As Early Predictor In PRECISE-AD Trial, Publication Reinforces Biomarker-Driven Design Ahead of Q2 2026 Interim Readout Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trialProMIS on track to leverage new plasma…
benzinga.com Dow Jumps 300 Points; Waldencast Shares Plunge 
benzinga.com Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher - benzinga.com ProMIS Neurosciences Announces 1-For-25 Reverse Stock Split, Effective Nov. 28 ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today…
- benzinga.com HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $4 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $4 price target.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $5 Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $6 to $5.
- benzinga.com ProMIS Neurosciences Q3 EPS $(0.24), Inline ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 177.42 percent decrease over earnings of $0.31 per share from the…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session